Research over several decades has identified many oncogenes and tumor suppressors that are frequently altered in various tumors. A substantial proportion of these oncogenic abnormalities is associated with growth signaling pathways. Recently, increasing evidence has suggested that growth signaling pathways directly control cell metabolism, growth and proliferation through the regulation of metabolic enzymes. In addition, individual metabolic enzymes have been reported to be mutated or amplified during tumor progression. Understanding how metabolic pathways are altered in tumors and how cancer cells benefit from tumor-specific metabolic changes may contribute to the identification of novel therapeutic targets and the development of more effective cancer therapies.
Although altered metabolism is beneficial to the cancer cell, it can create an increased demand for nutrients to support cell growth and proliferation. At the same time, the inner mass of a tumor may lack adequate nutrients before sufficient angiogenesis has occurred. Metabolic stress is a strong inducer of autophagy, a catabolic process leading to degradation of cellular components through the lysosomal system. Cancer cells use autophagy as a survival strategy to provide essential biomolecules required for cell viability under metabolic stress. In contrast, basal autophagy maintains intracellular organelle homeostasis by eliminating damaged proteins and organelles, which prevents generation of excess reactive oxygen species (ROS) and genome instability. Thus, autophagy is thought to have a key role in the suppression of tumorigenesis. Understanding the context-dependent role of autophagy in cancer development should present new opportunities for the design of cancer therapeutics.
In the first section of this review we summarize recent progress in identifying enzymes that contribute to the altered metabolism of cancer cells and in exploiting these enzymes as therapeutic targets. In particular, recent findings indicate that altered metabolism in cancer cells relies on the preferential use of alternative isoforms of enzymes or genomic amplification of enzymes involved in glucose and amino acid metabolism. In the second section, we discuss how cancer cells adapt to bioenergetic challenges by using autophagy as a cell survival strategy and summarize ongoing efforts to target autophagy in combination with conventional chemotherapy.
Metabolic enzymes altered in cancer cells
Cancer cells maintain their growth advantage through persistent activation of growth signaling pathways and inactivation of tumor suppressors. Canonical oncogenic signaling pathways, such as phosphatidylinositol 3−kinase (PI3K)-AKT/Protein Kinase B (PKB) and mammalian target of rapamycin (mTOR), directly reprogram core carbon metabolism, leading to greater nutrient uptake and greater macromolecular biosynthesis to support cell proliferation. Indeed, several metabolic enzymes, such as hexokinase 2 (HK2), lactate dehydrogenase A (LDHA) and pyruvate dehydrogenase kinase 1 (PDK1), are direct targets of oncogenic transcription factors, such as MYC and hypoxia-inducible factor-1α (HIF-1α). Moreover, emerging evidence suggests that metabolites derived from altered metabolism influence oncogenic signaling pathways in a reciprocal manner, and that such interactions may be the basis for tumor progression and/or resistance to conventional chemotherapeutic approaches. The regulatory connections between signaling pathways and metabolic enzymes have been extensively reviewed 1, 2 .
Various approaches to target oncogenic signaling pathways have been explored for the past 20 years and have shown great success in clinical trials. More recently, metabolic alterations involved in cancer progression have become targets for pharmaceutical development. Table 1 lists the metabolic enzymes that have been investigated in oncology clinical trials. Additional metabolic enzymes are being studied to determine their roles in the progression of various cancers and their potential as therapeutic targets (Fig. 1) The metabolism of cancer cells is reprogrammed both by oncogene signaling and by dysregulation of metabolic enzymes. The resulting altered metabolism supports cellular proliferation and survival but leaves cancer cells dependent on a continuous supply of nutrients. Thus, many metabolic enzymes have become targets for new cancer therapies. Recently, two processes-expression of specific isoforms of metabolic enzymes and autophagy-have been shown to be crucial for the adaptation of tumor cells to changes in nutrient availability. An increasing number of approved and experimental therapeutics target these two processes. A better understanding of the molecular basis of cancer-associated metabolic changes may lead to improved cancer therapies.
utilization of glucose, an observation that is probably the first evidence of metabolic alterations in cancer 3 . Whereas normal cells direct glucose to mitochondrial oxidative phosphorylation to generate ATP when oxygen is abundant, tumor cells generally exhibit greater glucose uptake, glycolytic flux and lactate secretion, regardless of oxygen availability. This phenomenon, called aerobic glycolysis, formed the basis for the development of 18 F-deoxyglucose positron emission tomography to image tumor development and regression in patients. Although the role and regulation of aerobic glycolysis in cancer cells are not fully understood, it has been suggested that this process supplies forms of energetic and anabolic substrates that favor massive macromolecular synthesis.
Understanding of the Warburg effect spurred efforts to preferentially eliminate cancer cells by targeting glucose metabolism. As glucose enters cells via specific transporters, a straightforward strategy would be to block glucose uptake by inhibiting glucose transporters. At least one small-molecule inhibitor of glucose transporters (silybin, also known as silibinin) has been developed, and clinical trials are ongoing to test its toxicity and efficacy 4, 5 . However, as glucose transporters have several isoforms, most of which are highly expressed in cancer cells, it will be challenging to develop compounds that inhibit all isoforms with an acceptable therapeutic window.
An alternative strategy for inhibiting glucose metabolism relies on the glucose analog 2-deoxy-d-glucose. This molecule enters cells via glucose transporters but is trapped as 2-deoxyglucose-6-phosphate after phosphorylation by hexokinase and cannot be further metabolized. Accumulation of 2-deoxyglucose-6-phosphate is thought to inhibit glycolytic enzymes and glucose catabolism. Although 2-deoxyd-glucose has been effective in preclinical and clinical studies, this treatment has not been fully explored because of concerns related to potential toxicity at high doses 6 .
More recently, it has been discovered that cancer cells seem to preferentially depend on specific isoforms of glycolytic enzymes 6 , prompting a search for isoform-specific inhibitors, which should increase drug specificity to cancer cells and avoid toxicity to normal cells. Key metabolic pathways and enzymes being investigated as potential targets include the muscle-specific isoform of hexokinase 2 and phosphofructokinase 2 (Fig. 1) . Tumor-specific expression of these isoforms has led to identification of isoform-specific inhibitors that have substantially suppressed tumor growth in preclinical studies 7, 8 and are being tested clinically ( Table 1) .
A rate-limiting step in glycolysis is conversion of phosphoenolpyruvate to pyruvate and generation of ATP by pyruvate kinase. A splicing variant of pyruvate kinase found in muscle, PKM2, is predominantly expressed in embryonic cells and tumor cells. The glycolytic intermediate fructose-1,6-bisphosphate binds to PKM2 and converts it to an enzymatically active form, whereas the tyrosine kinase signaling pathway inactivates PKM2 through the release of fructose-1,6-bisphosphate from PKM2 (ref. 9). Because most cancer cells exhibit constitutively active tyrosine kinase signaling, their level of PKM2 enzyme activity is lower. This has been proposed to be important for cell proliferation, as low PKM2 activity leads to accumulation of glycolytic intermediates, many of which either are precursors of macromolecular synthesis, such as nucleotides and amino acids, or can be used for generation of NADPH 10 . Later studies have suggested that phosphoenolpyruvate acts as a phosphate donor for the upstream enzyme phosphoglycerate mutase in PKM2-expressing cells, which further promotes glycolysis and biosynthetic processes 11 . Indeed, PKM2 cells maintain higher flux to the serine synthetic pathway 12 . The regulation of PKM2-mediated serine synthesis may be important for tumor growth and mammalian target of rapamycin complex 1 (mTORC1) signaling (see below) 12, 13 . On the basis of these data, a variety of PKM2-specific small-molecule inhibitors or activators have been investigated for their therapeutic potential in preclinical studies [14] [15] [16] , and some are being tested in clinical trials 6 (Table 1) .
Generation and disposal of lactate, the end product of glycolysis, has been extensively studied in connection with cancer therapy. Because lactate dehydrogenase converts pyruvate to lactate while oxidizing NADH to NAD + to support continued glycolytic flux, this enzyme has been considered one of the critical targets for suppressing elevated glycolysis. Lactate dehydrogenase A (LDHA), an isoform of lactate dehydrogenase, is preferentially expressed in many cancers and is a transcriptional target of MYC and HIF-1α. RNA interference (RNAi) knockdown experiments in various cancer cells have shown that LDHA has an important role in tumor growth [17] [18] [19] . A natural phenol derivative, gossypol, and its derivatives compete with NADH binding to lactate dehydrogenase and inhibit lactate dehydrogenase activity. Despite its lack of specificity, gossypol is being tested in clinical trials for various cancers 20 . The gossypol analogs have been screened for small-molecule inhibitors specific for LDHA. Among them, 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid (FX11) effectively inhibits cancer cell growth in vitro and in vivo by increasing oxidative stress 21 . More recently, N-hydroxyindole-based compounds npg r e v i e w have been identified as isoform-specific inhibitors of LDHA that compete with its substrates pyruvate and the cofactor NADH 22 . Pyruvate dehydrogenase kinase 1 (PDK1) is another transcriptional target of MYC and HIF-1α that seems to have a critical role in many cancers. It inactivates pyruvate dehydrogenase, which converts pyruvate to acetyl-CoA in the mitochondria. As a result, pyruvate is shuttled from the tricarboxylic acid cycle to produce lactate. Accordingly, specific inhibitors of PDK1 can block aerobic glycolysis and increase the rate of oxidative phosphorylation. For example, dichloroacetate, which is widely used for the treatment of lactic acidosis, has shown suppression of tumor growth in pre-clinical cancer models as well as in clinical trials of primary glioblastoma [23] [24] [25] (Table 1) , although its mechanism of action requires further investigation as it seems that this pyruvate mimetic compound lacks isoform selectivity among PDKs.
Lactate accumulated inside cancer cells is exported through the monocarboxylate transporter family. Impaired function of monocarboxylate transporters causes substantial defects in cancer cell proliferation and tumor growth, indicating that cancer cells depend on efficient lactate secretion 26, 27 . Moreover, secreted lactate can be taken up by an isoform of monocarboxylate transporter, MCT1, and used as a fuel source to support proliferation of neighboring cells that are relatively oxidative. This suggests that in the same tumor, cancer cells with diverse metabolic profiles exchange their metabolites for survival and growth in a symbiotic manner. Several compounds that block the function of MCT1 are being developed as potential cancer therapeutics [28] [29] [30] (Table 1) .
Many compounds targeting glycolytic enzymes have synergistic anticancer effects in combination with conventional chemotherapy or radiotherapy and with pathway-targeted agents. At present, some combinations with agents targeting glucose metabolism have shown promise in clinical trials, and various enzymes involved in the reactions branching from glucose metabolism that are altered in cancer cells are also being actively investigated 31 (Fig. 1) .
Glutamine metabolism. Although the initial studies of cancer cell metabolism focused on glucose, it is now clear that metabolism of amino acids and fatty acids is also reprogrammed to provide the building blocks for cancer cell growth and proliferation. Glutamine is the most abundant amino acid in the blood and a major source of nitrogen for the synthesis of nucleotides, amino acids and glutathione. In highly proliferative cells, it serves as a carbon source to replenish the tricarboxylic acid cycle to support cell bioenergetics and anabolic reactions. Several groups have recently proposed that cancer cells grown in hypoxic conditions increase their dependence on glutamine metabolism, as glutamine-derived α-ketoglutarate can undergo reductive carboxylation to produce citrate and lipids [32] [33] [34] . Therefore, glutamine metabolism in hypoxic cancer cells seems to be an essential pathway and an attractive therapeutic target.
After being taken up by cells, glutamine is converted to glutamate by the mitochondrial enzyme glutaminase. Glutamate is subsequently converted to α-ketoglutarate by either glutamate dehydrogenase or aminotransferases. As an intermediate of the tricarboxylic acid cycle, α-ketoglutarate can provide carbon backbones for cellular anabolic reactions 35 (Fig. 1) . Although the oncogenic signaling pathways involved in rewiring glutamine metabolism are not fully understood, multiple reports have suggested that the oncogenic transcription factor MYC controls glutamine catabolism by regulating expression of glutamine transporters and enzymes involved in glutaminolysis 35, 36 . In addition, MYC-overexpressing cells are markedly sensitive to glutamine deprivation, suggesting that they are addicted to glutamine 35, 37 . Recently, Myc-induced tumorigenesis has been associated with glutamine metabolism, as shown by the correlation between Myc expression and the metabolic profiles of mouse tumors 38 .
Glutaminase has two isoforms. Glutaminase 1 (GLS1) is thought to be the primary enzyme involved in glutaminolysis 35, 36 , whereas GLS2 seems to have a different function related to the antioxidant system 39 . Recently, GLS1 was identified using unbiased high-throughput npg VOLUME 30 NUMBER 7 JULY 2012 nature biotechnology r e v i e w screening as a target of a small-molecule inhibitor that blocks RhoGTPase-driven transformation 40 . Moreover, an isoform of GLS1, glutaminase C, is considered an important target owing to its elevated level in tumors showing glutamine addiction. Recent structure-based studies suggest that its activity is regulated by inorganic phosphate, which is highly enriched in mitochondria under hypoxia 41, 42 . Several glutamine analogs, including the compound 6-diazo-5-oxo-l-norleucine, have been tested as therapeutic agents preclinically and clinically. Although treatment with these agents has led to substantial inhibition of cancer cell growth in vitro and in mouse xenografts, the compounds are highly toxic owing to their lack of specificity 43 . Recently, a GLS1-specific inhibitor, bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES), was identified 44 and shown to substantially inhibit cancer cell growth in vitro and in mouse tumor models 38, 45 . As a selective inhibitor, BPTES may achieve a larger therapeutic window than glutamine analogs because specific inhibition of GLS1 would suppress a tumor relying on glutaminolysis without affecting other important functions of glutamine in normal tissues.
Another glutaminolysis enzyme, glutamate dehydrogenase, is important for glioblastoma cell survival under conditions in which glucose catabolism is impaired or the AKT pathway is inhibited 46 . Epigallocatechin gallate, a potent and specific inhibitor of glutamate dehydrogenase, blocks glutaminolysis and sensitizes glioblastoma cells to glucose deprivation 46, 47 . As glutamine can support cancer cell survival under glucose limitation and hypoxia, the suppression of glutamine catabolism would be synergistic with inhibition of growth signaling pathways related to glucose catabolism.
Serine synthetic pathways. Glycolytic intermediates derived from enhanced glycolysis in cancer cells can be shunted to generate nonessential amino acids, lipids and nucleotides that facilitate cancer cell growth and proliferation. For example, cells expressing PKM2 accumulate the glycolytic intermediate 3-phosphoglycerate, which can be shunted to the serine synthetic pathway. As a result, PKM2 cells (that is, cancer cells) can maintain mTORC1 activity and proliferation in serine-depleted medium, whereas PKM1 cells (that is, normal cells) cannot 12, 13 . Notably, the rate-limiting enzyme involved in branching glycolysis to the serine synthetic pathways, phosphoglycerate dehydrogenase, is amplified in a subset of melanoma and estrogen receptornegative breast cancer 48, 49 , suggesting that greater flux into the serine synthetic pathway provides selective advantage to tumor cells. Overexpression of this gene leads to cellular transformation, and RNAi suppression of PHGDH leads to inhibition of cancer cell proliferation and transformation 48, 49 . Therefore phosphoglycerate dehydrogenase is an attractive metabolic target for cancer therapeutics, together with other enzymes involved in the serine synthetic pathway.
Serine is an important nonessential amino acid that can be used for synthesis of other amino acids, such as glycine and cysteine, and for generation of phospholipids. In addition, when serine is metabolized to glycine, tetrahydrofolate is converted to 5,10-methylenetetrahydrofolate, a critical step in maintaining the folate cycle for nucleotide synthesis 50 (Fig. 1) . The dependence of cancer cells on the folate cycle has been demonstrated by successful development of antifolate drugs, one of the earliest chemotherapies developed in the last century and widely used in the clinic to treat various types of cancer ( Table 1) . Examples include 5-fluorouracil, which inhibits thymidine synthesis, and methotrexate, which blocks purine synthesis by inhibiting dihydrofolate reductase, which converts dihydrofolate to tetrahydrofolate ( Table 1) .
Autophagy
Autophagy is a self-degradation process whereby cytosolic components and organelles are sequestered in double membrane-bound vesicles and delivered to lysosomes for degradation and recycling (Fig. 2) . In normal tissue, autophagy maintains cellular homeostasis by clearing damaged organelles or misfolded proteins. However, the role of autophagy in cancer is complex and paradoxical as it is an npg r e v i e w adaptive process that is responsive to changes in the cellular microenvironment. Thus, autophagy can either suppress or support the growth of tumor cells depending on the cellular context.
The role of autophagy in cancer is context dependent. The role of autophagy as a tumor-suppressive process emerged in early studies showing that monoallelic deletion of the autophagy gene BECN1 is present in various human cancers, and that mice heterozygous for Becn1 (also known as Beclin1) develop multiple spontaneous malignancies 51, 52 . Moreover, some gastric cancers carried nonsense mutations of ultraviolet radiation resistance-associated gene (UVRAG), a Becn1-binding autophagy regulator 53 . A recent study found that mice with systemic mosaic deletion of atg5 or liver-specific deletion of atg7 have a high incidence of benign liver adenoma development, suggesting that autophagy suppresses tumor initiation 54 . Furthermore, p62, an autophagy substrate protein, accumulates in autophagy-deficient cells after metabolic stress, leading to increases in damaged mitochondria, oxidative stress and DNA damage through activation of nuclear factor-κB (NF-κB) 55, 56 .
In contrast, autophagy has been proposed to be a prosurvival process in cells exposed to metabolic stress. When growth factor-dependent cells are subjected to metabolic stress after growth factor deprivation, they use autophagy to generate additional bioenergetic substrates to support cell survival 57 . Similar results have been observed in established tumors: autophagy promotes cell survival in the center of the tumor, which is probably deprived of nutrients and oxygen 58 . In addition, cells genetically deficient in autophagy genes, such as BECN1 or atg5, are sensitive to metabolic stress 59, 60 . On the basis of recent immunohistochemical analysis of tumor samples, expression of mammalian homologs of Atg8, γ-aminobutyric acid A receptor-associated protein (GABARAP) and microtubule-associated protein 1 light chain 3 (LC3) is increased in various tumor tissues compared with normal tissues, and their expression correlates with tumor progression and poor therapeutic outcome 61, 62 . This indicates that autophagy is actively induced in advanced stages of tumorigenesis.
Autophagy not only supports adaptation to the tumor microenvironment but also promotes cell survival under certain oncogenic stresses, as illustrated in the examples below. Studies using genetically engineered mouse models of cancer indicate that autophagy is indispensable for tumor development and maintenance, regardless of nutrient availability. Targeted deletion of the autophagy gene RB1CC1 (also known as FIP200) leads to a substantial delay of mammary tumor progression in a mouse breast cancer model induced by the polyomavirus middle T (PyV-MT) oncogene 63 . Multiple studies have suggested that autophagy is required for RAS-induced transformation in vitro and RAS-driven tumorigenesis [64] [65] [66] . Moreover, primary tumor cells and cell lines from pancreatic tumors with KRAS mutations show elevated autophagy necessary for cancer cell growth in vitro 67 .
Despite increasing evidence supporting the prosurvival role of autophagy in established cancer, the mechanisms whereby autophagy supports energy-demanding cancer cell metabolism are largely unknown. One hypothesis is that metabolites derived from autophagic degradation of cellular components might be used as bioenergetic and anabolic substrates for adaptation and growth of cancer cells. Indeed, metabolic analysis shows that autophagy is required to maintain the full activities of the mitochondrial tricarboxylic acid cycle and oxidative phosphorylation after RAS activation 66 . Moreover, melanoma cell lines established from clinical samples depend on extracellular leucine, which can be rescued by autophagy activation 68 .
Another remaining question in autophagy research is what triggers the autophagic response. Deprivation of essential amino acids activates autophagy through inhibition of the mTOR pathway. Notably, our group 69 and others 70 have shown that ammonia, a metabolic byproduct of amino acid catabolism, including glutaminolysis, acts as an autophagy inducer. Interestingly, this form of autophagy is independent of the mTOR-unc-51-like protein kinase (ULK) pathway 69 . These observations suggest that autophagy induction is linked to either relative lack of or excess nitrogen, sensed by distinct mechanisms. How increased intracellular nitrogen is sensed and affects cancer development is still unclear. Considering that tumors with activated oncogenes, such as MYC or RAS, rely on glutaminolysis to generate bioenergetic fuel 35, 71 , we speculate that elevated autophagy in these oncogene-driven tumors might be initiated through mechanisms sensing excess nitrogen.
As is clear from the above discussion, the role of autophagy in tumor initiation and progression is complex. Autophagy may suppress tumor growth in the tumor-initiation stage, whereas in established tumors, it may fulfill metabolic needs of cancer cells during oncogene activation or nutrient limitation by providing a mechanism to recycle intracellular carbon and nitrogen. The cellular context of tumors (origin, stage and genetic makeup) influences the outcome of the autophagy response and must be considered when using autophagy modulation in cancer therapy.
Autophagy as a therapeutic target. Given the critical roles of autophagy in tumor progression and maintenance, various preclinical and clinical studies have been undertaken to develop therapeutic agents targeting autophagy. As most anticancer agents inevitably cause cellular stress, autophagy is often activated in cancer cells after drug treatment. Indeed, many therapies targeting growth factor signaling-either singly or in combinations targeting two different pathways-lead to autophagy induction ( Table 2) . For example, several allosteric and catalytic inhibitors of mTOR, PI3K-AKT, and the tyrosine kinase signaling and activators of energy sensing pathway (e.g., 5′-AMP-activated protein kinase) induce autophagy in cells. Various agents targeting cellular processes such as histone deacetylation, proteasomal degradation, apoptosis and glycolysis have also been suggested to trigger autophagy ( Table 2) . It was originally proposed that autophagic cell death is part of the mechanism of action of anticancer drugs. Indeed, some combinatorial treatments with the above drugs have shown synergistic effects on the induction of cell death, which is reduced by knockdown of autophagy genes, suggesting that autophagy induced by chemotherapy contributes to its anticancer effect ( Table 2) . However, it has been suggested that the increased autophagy seen during anticancer drug treatment could also be a survival response of the dying cells rather than a cause of cell death 72 . As many autophagy inducers have shown limited success in clinical trials, it is necessary to assess the contribution of autophagy in the mechanisms of action of these drugs. Moreover, a growing body of evidence indicates that stress-induced autophagy in tumor cells might drive cellular resistance to chemotherapy and facilitate tumor dormancy 73, 74 .
In light of the above findings, inhibition of autophagy combined with conventional chemo/radiotherapy may be a useful approach clinically, and combination therapies with autophagy inhibitors and chemotherapeutics are being tested in clinical trials. A series of studies have reported that cancer therapeutics that induce autophagy synergize with autophagy inhibitors for anticancer effects both in many cancer cell lines and in xenograft models 75, 76 . The most common autophagy inhibitors used in clinical trials are chloroquine and hydroxychloroquine. These agents are registered antimalarial drugs that inhibit lysosomal acidification and impair autophagosome fusion with lysosomes and degradation 77 . Preclinical studies using a Myc-induced npg VOLUME 30 NUMBER 7 JULY 2012 nature biotechnology r e v i e w mouse lymphoma model suggest that inhibition of autophagy by treatment with hydroxychloroquine increases cell death and substantially impairs recurrence of tumors after chemotherapy 78, 79 . Clinical trials involving chloroquine-and hydroxychloroquine-mediated autophagy inhibition for cancer therapy are ongoing and listed at http://www.clinicaltrial.gov/.
In addition to chloroquine derivatives, various other putative autophagy inhibitors have been studied for their antitumor effects in vitro and in vivo ( Table 2) . However, these agents have nonspecific effects on other cellular functions, such as endocytosis (e.g., 3-methyladenine) and lysosomal function (e.g., bafilomycin A). Targeting key autophagy proteins would be a more potent and specific approach. Several components of the autophagic machinery are druggable and serve as potential therapeutic targets. These include the ULK1 and ULK2 serine-threonine protein kinases, the enzymes involved in ubiquitin-like conjugation systems (e.g., E1-like ubiquitination enzyme Atg7 and E2-like enzymes Atg3 or Atg10) and the cysteine protease Atg4. Moreover, Vps34, a class III PI3K, could be targeted as it is a key autophagy regulator, although it also regulates normal endocytosis. In addition to pharmacological inhibitors, gene interference using small interfering RNA against various autophagy proteins has a synergistic effect in combination with other treatments in preclinical studies. Accordingly, a deeper understanding of the molecular basis of autophagy induction and execution could help identify more therapeutic targets for cancer that can be drugged alone or in combination.
Conclusions
Cancer cells display multiple layers of metabolic alterations that affect cell proliferation and survival through dysregulation of oncogenic pathways and tumor suppressors and through changes in the microenvironment and stromal cells. Increasing evidence indicates that cancer cell metabolism is reprogrammed through expression of specific isoforms of metabolic enzymes that exhibit distinct enzymatic activities and substrate preferences. Preclinical studies suggest that tumor cells may be addicted to these enzyme variants. As metabolic enzymes could be easier to target compared with transcription factors and signaling proteins, it may be possible to develop isoform-specific small-molecule inhibitors that achieve a greater therapeutic window compared with conventional chemotherapeutics. The identification of patients who may benefit from targeted metabolic therapies will be facilitated by a better understanding of the signaling pathways leading to alternative splicing events that give rise to cancer-specific isoforms of metabolic enzymes. Recent insights into genomic amplification and mutation of metabolic enzymes 48, 49, 80, 81 also provide a source of new targets. Finally, clinical application of emerging knowledge about autophagy will require further investigation of the roles of this process in cancer development. For example, identifying the signaling pathways that regulate autophagy activity at different stages of tumor progression should help in deciphering the mechanisms of tumor resistance to targeted therapies and in designing combinatorial therapies that overcome drug resistance. Successful targeting of autophagy in cancer therapy also requires molecular analysis of the components of distinct forms of autophagy, as well as their interactions with other cellular and metabolic processes. 
